Na Li, MD, PHD

About

Gender

Female

Additional languages

Mandarin

Biography

As a gastroenterologist and hepatologist at The Ohio State University Wexner Medical Center, I see patients in clinic and perform endoscopic procedures. I enjoy working at OSU because it provides comprehensive support for patient care and a robust research environment. This makes it possible for me to provide the most appropriate and individualized care to my patients. In addition, patients also have the opportunity to receive the latest treatments through clinical trials.

My clinical focus is Non-Alcoholic Fatty Liver Disease (NAFLD), which affects about one-quarter of people worldwide. Patients with obesity and type 2 diabetes are at particularly high risk for disease progression (NASH), which often leads to poor health outcomes. Therefore, it is important to raise public awareness of NAFLD and intervene at early stages of the disease. Optimized care for patients with NAFLD requires teamwork among multi-specialty physicians, medical counselors, patients, and their family members. I feel fortunate to be a part of this team and happy to make such a positive impact on my patients’ lives.

When I am not working, I enjoy spending time with family, dancing, and traveling.

Learn more about receiving a tailored approach to treating fatty liver disease at the Ohio State Wexner Medical Center: https://wexnermedical.osu.edu/liver-diseases/fatty-liver-disease

Highlights

• CURRENTLY AVAILABLE CLINICAL TRIALS ON NAFLD AS A PRINCIPLE INVESTIGATOR
• NAVIGATE study - A seamless, adaptive, phase 2b/3, double-blind, randomized, placebo-controlled, multicenter, international study evaluating the efficacy and safety of belapectin for the prevention of esophageal varices in NASH cirrhosis. Status: Active enrollment.
• ESSENCE study - The effect of semaglutide in subjects with non-cirrhotic NASH (phase 3). Status: Expected enrollment in September 2021.
• ENLIVEN study - A randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and Tolerability of BIO89-100 in subjects with biopsy-confirmed NASH (phase 3). Status: Expected enrollment in October 2021.
• FASCINATE-2 study - A phase 2b, multi-center, double-blind, randomized, placeobo-controlled study of the safety and efficacy of TVB-2640 in subjects with NASH. Status: Expected enrollment in October 2021
• REVERSE study - A phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). Status: completed enrollment.
• For more information on these clinical trials, contact Gabrielle Volk (gabrielle.volk@osumc.edu).

Conditions and expertise

• Celiac Disease
• Colonoscopy
• Constipation
• Diarrhea
• Digestive System Diseases
• Fatty Liver
• Gastric Acid Reflux Disease
• Gastroenteritis
• Gastroscopy
• Hepatitis
• Inflammatory Bowel Diseases
• Irritable Bowel Syndrome
• Liver Cirrhosis
• Liver Diseases
• Peptic Ulcer

Credentials

Ratings and reviews

The overall patient satisfaction rating is an average of all patient responses to the six doctor communication related questions shown below from the Clinician and Group Consumer Assessment of Healthcare Providers and Systems survey. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page.

The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of Ohio State Wexner Medical Center.